Cipla acquires brand, trademark rights for anti-diabetic drug Vysov in India
Cipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Vildagliptin
Eris Lifesciences acquires trademark Zomelis (for Vildagliptin) from Novartis AG for India market
Zomelis is used in the treatment of type 2 diabetes and comes under a new class of anti-diabetic drugs known as DPP 4 inhibitors
Morepen Labs adds three new drugs to its API Portfolio
The three bulk drugs/APIs are Rivaroxaban, Vildagliptin and UDCA will augment Morepen’s presence in the cardiac and diabetic…